Xuan Gu Bao·2025-11-24 12:09Buyback - Naxin Micro plans to repurchase company shares for an amount between 200 million to 400 million RMB [1] Mergers and Acquisitions - Shangwei Co. intends to invest 520 million RMB to acquire a controlling stake of 51% in Sichuan Zhongfu Taihua New Material Technology Co., which is currently in the process of building its production lines and has not yet officially commenced operations, except for a small hydrogen peroxide business [2] Investment Cooperation and Operational Status - Industrial Fulian refutes rumors regarding a downward adjustment of its fourth-quarter profit target, stating that overall operations, including the shipment of products like GB200 and GB300, are proceeding as planned with strong customer demand [3] - Longpan Technology has signed a significant contract for the sale of 150,000 tons of lithium iron phosphate cathode materials from 2025 to 2030, with a supplementary agreement for an additional 1.3 million tons, estimating total sales exceeding 45 billion RMB [3] - Haichuang Pharmaceutical has received clinical trial approval for its oral PROTAC drug HP518 for the treatment of advanced prostate cancer, with no similar products approved for market in China or abroad [3] - Panjiang Co. is increasing capital by 1.334 billion RMB to fund the construction of the Guizhou Energy Puding Power Plant project [4] - Zhongding Co.'s subsidiary has become a supplier for liquid cooling dummy loads, with an expected project total of 15 million RMB [5] - Dongfang Zirconium's wholly-owned subsidiary is investing in a project to produce 60,000 tons of battery-grade chlorinated zirconia and 12,000 tons of high-purity zirconium-hafnium separation oxides, with a budget of 737 million RMB [5] - Tianfu Cultural Tourism has signed a cooperation framework agreement for the integration of film and tourism development with the Deyang Bureau of Culture, Radio, Television and Tourism, and Aba Dajiu Zhai Tourism Group [6] - Zai Jing Pharmaceutical's injectable ZG006 for the treatment of advanced neuroendocrine cancer has been included in the list of breakthrough therapy designations [7] - Jinbei Automotive has signed a strategic framework agreement with JD.com to become a supplier for JD's automotive business [8] - Jingyan Technology plans to use up to 1.6 billion RMB of idle funds for entrusted wealth management [9]